Soo Yong Tan

Tan Soo Yong

Appointment(s)
  • Associate Professor, Department of Pathology
Administrative Appointment(s)
  • Head, Department of Pathology, NUS Yong Loo Lin School of Medicine
  • Chief, Department of Pathology, National University Health System
Joint Appointment(s)
  • Senior Principal Investigator, Institute of Cell and Molecular Biology, A*STAR
  • Head, Advanced Molecular Pathology Laboratory, Institute of Cell and Molecular Biology, A*STAR
  • Visiting Professor, University Malaya, Malaysia
  • Visiting Professor, Guangdong Academy of Medical Sciences and Guangdong Hospital, China
  • Senior Consultant, Regulatory Policy and Licensing Division, Ministry of Health, Singapore
  • Senior Consultant, Manpower Development and Professional Standards Division, Ministry of Health, Singapore
  • Visiting Consultant, Division of Medical Sciences, National Cancer Centre, Singapore
  • Visiting Consultant, National Skin Centre, Singapore
  • Singapore Representative to the Advisory Board of the IAEA
  • Consultant, Johnson & Johnson, Inc.
  • Consultant, Abbott Molecular
  • Key Opinion Leader, Ventana, USA
  • Chairman, Biobanking Subcommittee, Asian Network of Research Resource Centres
  • Member, Diagnostic Hotspot Advisory Panel, Exploit Technologies, A*STAR
  • Member, Advisory Group on the Sharing of Research Data, Biomedical Research Council
  • Member, Advisory Board, Roche-Ventana
  • Member, Advisory Board, MiRXES
  • Member, Hub Evaluation Panel, Diagnostic Hub, ETPL
  • International Advisor (West Pacific), Royal College of Pathologists
  • Member, International Lymphoma Study Group
Academic Qualifications
  • DPhil (Oxon), Oxford University, United Kingdom
  • MBBS, National University of Singapore, Singapore
  • MRCPath, Royal College of Pathologists, United Kingdom
  • FRCPath, Royal College of Pathologists, United Kingdom
  • DMJ (Pathology), Society of Apothecaries of London, United Kingdom
  • DipRCPath, Royal College of Pathologists, United Kingdom
Research Interest(s)
  • Haematopathology
  • Haematology Oncology
  • Lymphoma
  • Leukaemia
Recent Publications
  • 1. Tan SY, Ooi AS, Ang MK, Koh M, Wong JC, Dykema K, Ngeow J, Loong S, Gatter K, Tan L, Lim LC, Furge K, Tao M, Lim ST, Loong F, Cheah PL, Teh BT. 2011 Mar. Nuclear expression of MATK is a novel marker of type II enteropathy-associated T-cell lymphoma. Leukemia. 25(3):555-7. doi: 10.1038/leu.2010.295. 21233830.
  • 2. Koo GC, Tan SY, Tang T, Poon SL, Allen GE, Tan L, Chong SC, Ong WS, Tay K, Tao M, Quek R, Loong S, Yeoh KW, Yap SP, Lee KA, Lim LC, Tan D, Goh C, Cutcutache I, Yu W, Ng CC, Rajasegaran V, Heng HL, Gan A, Ong CK, Rozen S, Tan P, Teh BT, Lim ST. 2012 Jul. Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. Cancer Discov. 2(7):591-7. doi: 10.1158/2159-8290.CD-12-0028. 22705984.
  • 3. Tan SY, Chuang SS, Tang T, Tan L, Ko YH, Chuah KL, Ng SB, Chng WJ, Gatter K, Loong F, Liu YH, Hosking P, Cheah PL, Teh BT, Tay K, Koh M, Lim ST. 2013 Aug. Type II EATL (epitheliotropic intestinal T-cell lymphoma): a neoplasm of intra-epithelial T-cells with predominant CD8αα phenotype. Leukemia. 27(8):1688-96. doi: 10.1038/leu.2013.41. 23399895.
  • 4. Tan D, Tan SY, Lim ST, Kim SJ, Kim WS, Advani R, Kwong YL. 2013 Nov. Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines. Lancet Oncol. 14(12):e548-61. doi: 10.1016/S1470-2045(13)70450-9. 24176573.
  • 5. Chen Y, Tan SY, Petersson BF, Khor YM, Gopalakrishnan SK, Tan D. 2016 Mar. Occult recurrence of monomorphic epitheliotropic intestinal T-cell lymphoma and the role of MATK gene expression in diagnosis. Hematol Oncol. doi: 10.1002/hon. 2288.26948059.